Huang Tzu-Chou, Lai Tzu-Hsien, Taiwan Headache Society Treatment Guideline Subcommittee Of Taiwan Headache Society
Acta Neurol Taiwan. 2017 Mar 15;26(1):33-53.
The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for migraine prevention in Taiwan. We assessed the results of new published drug trials, information from medical database and referred to the latest guidelines published. After comprehensive discussion, we proposed Taiwanese consensus about the preventive treatment for migraine including recommendation levels, strength of evidences, and related prescription information regarding dosage and adverse effects. This guideline is updated from earlier version published in 2008. Migraine preventive medications currently available in Taiwan can be categorized into ß-blockers, antidepressants, calcium channel blockers, anticonvulsants, nonsteroid anti-inflammatory drugs, OnabotulinumtoxinA and miscellaneous medications. Propranolol has the best level of evidence and fewer side-effects, and is recommended as the first-line medication for episodic migraine prevention. Valproic acid, topiramate, flunarizine and amitriptyline are suggested as the second-line medications. The rest medications are used when the above medications fail. OnabotulinumtoxinA and topiramate are recommended for chronic migraine prevention. Those other medications used for episodic migraine could also be used as a second-line option. It is not recommended to use migraine preventive medication during pregnancy or lactation. For those women with menstrual migraine, nonsteroid anti-inflammatory drugs and triptans can be used for prevention during the menstrual period. The levels of evidences for migraine preventive medications in children/adolescents and elderly are low. The preventive medications should follow the "start low and go slow" doctrine to reach an effective dosage. This can prevent adverse events and improve tolerance. The efficacy of preventive medications cannot be evaluated until 3 to 4 weeks after treatment. If the improvement of migraine maintains for 6 months, physicians can gradually taper the medications. Physicians should notify the patients not to overuse acute medications during migraine prevention treatment.
台湾头痛学会治疗指南小组委员会评估了台湾目前用于预防偏头痛的药物。我们评估了新发表的药物试验结果、医学数据库中的信息,并参考了最新发布的指南。经过全面讨论,我们提出了台湾关于偏头痛预防性治疗的共识,包括推荐级别、证据强度以及有关剂量和不良反应的相关处方信息。本指南是对2008年发布的早期版本的更新。台湾目前可用的偏头痛预防性药物可分为β受体阻滞剂、抗抑郁药、钙通道阻滞剂、抗惊厥药、非甾体抗炎药、A型肉毒毒素和其他药物。普萘洛尔有最佳的证据级别且副作用较少,被推荐作为发作性偏头痛预防的一线药物。丙戊酸、托吡酯、氟桂利嗪和阿米替林被建议作为二线药物。当上述药物无效时使用其余药物。A型肉毒毒素和托吡酯被推荐用于慢性偏头痛预防。那些用于发作性偏头痛的其他药物也可作为二线选择。不建议在怀孕或哺乳期使用偏头痛预防性药物。对于那些有月经性偏头痛的女性,非甾体抗炎药和曲坦类药物可在月经期用于预防。儿童/青少年和老年人偏头痛预防性药物的证据级别较低。预防性药物应遵循“从小剂量开始,缓慢增加”的原则以达到有效剂量。这可以预防不良事件并提高耐受性。预防性药物的疗效在治疗后3至4周才能评估。如果偏头痛的改善持续6个月,医生可以逐渐减少药物剂量。医生应告知患者在偏头痛预防治疗期间不要过度使用急性发作药物。